Precision BioSciences Appoints Melinda Brown to Board of Directors
businesswire.com
news
2022-05-31 00:00:00

May 31, 2022 08:00 AM Eastern Daylight Time DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUSÂ®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies.
